LF 080133
Alternative Names: LF 08-0133Latest Information Update: 05 Oct 2007
Price :
$50 *
At a glance
- Originator Fournier Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 30 Mar 2001 Phase-I clinical trials for Atherosclerosis in France (Unknown route)
- 29 Dec 1999 LF 080133 is available for licensing (http://www.groupe-fournier.com/)
- 15 Nov 1999 Preclinical development for Atherosclerosis in France (Unknown route)